Download
s10557-020-07040-7.pdf 277,99KB
WeightNameValue
1000 Titel
  • Metformin Is Associated with Reduced Tissue Factor Procoagulant Activity in Patients with Poorly Controlled Diabetes
1000 Autor/in
  1. Witkowski, Marco |
  2. Friebel, Julian |
  3. Tabaraie, Termeh |
  4. Grabitz, Sinah |
  5. Dörner, Andrea |
  6. Taghipour, Lena |
  7. Jakobs, Kai |
  8. Stratmann, Bernd |
  9. Tschoepe, Diethelm |
  10. Landmesser, Ulf |
  11. Rauch, Ursula |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-09-17
1000 Erschienen in
1000 Quellenangabe
  • 35(4):809-813
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s10557-020-07040-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266708/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Metformin is the first-line antidiabetic drug and shown to reduce cardiovascular risk independent from its glucose lowering action. Particularly in poorly controlled diabetes, tissue factor (TF) is expressed in the vasculature and accounts for thromboembolic complications. Here, we aimed to assess the effect of metformin on TF activity and markers of vascular inflammation in poorly controlled type 2 diabetes.!##!Methods!#!In a cohort of patients with uncontrolled type 2 diabetes (glycosylated hemoglobin 8.39 ± 0.24%, 68.1 ± 2.6 mmol/mol, n = 46) of whom half of the individuals were treated with metformin and the other half did not receive metformin as part of an anti-diabetic combination therapy, we assessed TF activity and markers of vascular inflammation. In vitro, human monocytic cells (THP-1) were exposed to metformin and TF expression measured in the presence and absence of the AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide riboside (AICAR) or the AMPK inhibitor compound C.!##!Results!#!In the patients, metformin treatment was associated with lower levels of TF protein (241.5 ± 19 vs. 315.4 ± 25 pg/mL, p = 0.03) and reduced TF activity (408.9 ± 49 vs. 643.8 ± 47 U/mL, p = 0.001) compared with controls. Moreover, the patients on metformin showed lower levels of vascular cell adhesion molecule (VCAM)1 (26.6 ± 1.4 vs. 35.03 ± 3.1 ng/mL, p = 0.014) and higher expression of miR-126-3p/U6sno (11.39 ± 2.8 vs. 4.26 ± 0.9, p = 0.006), a known post-transcriptional down regulator of TF and VCAM1. In vitro, metformin dose-dependently reduced lipopolysaccharide (LPS)-induced TF expression in THP-1 cells. The AMPK activator AICAR alone lowered TF expression in THP-1, while the AMPK inhibitor compound C abrogated the metformin-dependent reduction in TF expression.!##!Conclusions!#!Our data are the first to report that metformin is associated with reduced plasma TF procoagulant activity possibly explaining-at least in part-the vasculoprotective properties of metformin.
1000 Sacherschließung
lokal Metformin/administration
lokal Hypoglycemic Agents/pharmacokinetics [MeSH]
lokal Leukocyte Count/methods [MeSH]
lokal Diabetes Mellitus, Type 2/drug therapy [MeSH]
lokal THP-1 Cells [MeSH]
lokal Heart Disease Risk Factors [MeSH]
lokal thrombosis
lokal Fibrinolytic Agents/administration
lokal Male [MeSH]
lokal microRNA
lokal Glycated Hemoglobin A/analysis [MeSH]
lokal Hypoglycemic Agents/administration
lokal diabetes mellitus
lokal Female [MeSH]
lokal Metformin/pharmacokinetics [MeSH]
lokal Thromboplastin/metabolism [MeSH]
lokal Humans [MeSH]
lokal Metformin
lokal MicroRNAs/metabolism [MeSH]
lokal Peroxidase/blood [MeSH]
lokal Middle Aged [MeSH]
lokal Vascular Cell Adhesion Molecule-1/blood [MeSH]
lokal Diabetes Mellitus, Type 2/blood [MeSH]
lokal Drug Resistance [MeSH]
lokal coagulation
lokal tissue factor
lokal cardiovascular disease
lokal C-Reactive Protein/analysis [MeSH]
lokal vascular complications
lokal vascular inflammation
lokal Diabetes Mellitus, Type 2/metabolism [MeSH]
lokal Short Communication
lokal Fibrinolytic Agents/pharmacology [MeSH]
lokal Thromboplastin/isolation
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/V2l0a293c2tpLCBNYXJjbw==|https://frl.publisso.de/adhoc/uri/RnJpZWJlbCwgSnVsaWFu|https://frl.publisso.de/adhoc/uri/VGFiYXJhaWUsIFRlcm1laA==|https://frl.publisso.de/adhoc/uri/R3JhYml0eiwgU2luYWg=|https://frl.publisso.de/adhoc/uri/RMO2cm5lciwgQW5kcmVh|https://frl.publisso.de/adhoc/uri/VGFnaGlwb3VyLCBMZW5h|https://frl.publisso.de/adhoc/uri/SmFrb2JzLCBLYWk=|https://frl.publisso.de/adhoc/uri/U3RyYXRtYW5uLCBCZXJuZA==|https://frl.publisso.de/adhoc/uri/VHNjaG9lcGUsIERpZXRoZWxt|https://frl.publisso.de/adhoc/uri/TGFuZG1lc3NlciwgVWxm|https://orcid.org/0000-0002-1544-7644
1000 Hinweis
  • DeepGreen-ID: 1329e6ef60074ebabca8e35c7498925c ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6470796.rdf
1000 Erstellt am 2023-11-18T08:53:36.903+0100
1000 Erstellt von 322
1000 beschreibt frl:6470796
1000 Zuletzt bearbeitet 2023-12-01T12:54:51.315+0100
1000 Objekt bearb. Fri Dec 01 12:54:51 CET 2023
1000 Vgl. frl:6470796
1000 Oai Id
  1. oai:frl.publisso.de:frl:6470796 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source